Hosted on MSN1mon
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...
Hosted on MSN14d
Depemokimab reviewed for asthma and CRSwNP in Asia
Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...
Nasdaq1mon
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
Pharmabiz13d
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP
GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...
PharmiWeb15d
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...